ChemoCentryx discovers, develops and commercializes new medicines for inflammatory disorders, cancer, autoimmune and infectious diseases by targeting the chemokine system, the master regulator of immune function. The Company is recognized as a world leader in biology, drug discovery and development based on the chemokine system. ChemoCentryx is developing first-in-class, oral therapies for diseases such as inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis and cancer. ChemoCentryx distinguishes itself through unparalleled chemokine system expertise, innovative technologies and a product-driven approach, which has yielded several exciting drug candidates and the largest pipeline of chemokine-based drugs in the industry.
|08/01/06||Series C||17.7M||Jennison Associates LLC, HBM Bioventures, OrbiMed Advisors LLC, Techne Corp., Alta Partners, GIMV||Unknown|